CureVac N.V.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00W9LXXJ4
CVAC
CureVac N.V.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
CureVac N.V.
ISIN
NL0015436031
TICKER
CVAC
MIC
XNAS
REUTERS
CVAC.OQ
BLOOMBERG
CVAC US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Tue, 12.11.2024
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024and Provides Business Update
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter
€400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to €551 million; expected c...
Thu, 07.11.2024
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
TÜBINGEN, Germany/BOSTON, USA – November 7, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will r...
Mon, 04.11.2024
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Experienced CFO and investment banker with 30-year track record will help drive CureVac’s transformation
TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmac...
Mon, 04.11.2024
CureVac to Present at the 12th International mRNA Health Conference
TÜBINGEN, Germany/BOSTON, USA – November 4, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that new and updated data will be share...
Mon, 28.10.2024
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
TÜBINGEN, Germany/BOSTON, USA – October 28, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced poster presentati...
Fri, 13.09.2024
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy
84% of immune responses were de novo, observed in pa...
Fri, 13.09.2024
CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy
84% of immune responses were de novo, observed in pa...
Thu, 12.09.2024
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints
Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone
GSK...
Thu, 12.09.2024
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints
Vaccine candidate based on CureVac’s proprietary second-generation mRNA backbone
GSK...
Mon, 09.09.2024
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
TÜBINGEN, Germany/BOSTON, USA – September 9, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the f...
Information on product placements
